SpringWorks Therapeutics ...

55.40
1.40 (2.59%)
At close: Feb 11, 2025, 3:59 PM
58.50
5.60%
After-hours Feb 11, 2025, 07:20 PM EST
undefined%
Bid 58.5
Market Cap 4.12B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.89
PE Ratio (ttm) -14.24
Forward PE n/a
Analyst Buy
Ask 58.65
Volume 7,129,610
Avg. Volume (20D) 1,721,973
Open 53.75
Previous Close 54.00
Day's Range 50.81 - 56.42
52-Week Range 28.21 - 60.00
Beta undefined

About SWTX

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the t...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2019
Employees 305
Stock Exchange NASDAQ
Ticker Symbol SWTX

Analyst Forecast

According to 6 analyst ratings, the average rating for SWTX stock is "Buy." The 12-month stock price forecast is $69, which is an increase of 24.55% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

SpringWorks Therapeutics Inc. is scheduled to release its earnings on Feb 20, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
+34.06%
SpringWorks Therapeutics shares are trading higher... Unlock content with Pro Subscription
4 weeks ago
-13.93%
SpringWorks Therapeutics shares are trading lower following Q4 and FY24 financial results